FarmaKology-Reuters Events : Pharma Predictions 2022-2027
After a staggering two years of unprecedented disruption and innovation, there’s no longer questions surrounding whether pharma can realize exceptional change. What’s less certain, however, is where and how pharma will direct its efforts to achieve ground-breaking transformation over the next five years.
In Reuters Events’ exclusive new report, ‘Pharma Predictions 2022-2027’ leaders across the industry have shared their predictions for pharma’s top priorities for the coming years, so you can see where our collective path may be headed.
In addition to forecasts from our very own Reuters Events Pharma team, read predictions from leading experts including:
Zhen Su, CEO, Marengo Therapeutics
Oscar Segurado, Chief Medical Officer, ASC Therapeutics
Eddie Power, VP, North America Medical Affairs, Pfizer
Victoria DiBiaso, Global Head, Patient Informed Development & Health Value Translation, Sanofi
Haider Alleg, Global Head of Digital, Ferring
Mark Montgomery, Head, Business Insights & Execution, Commercial Acceleration, Novartis
Keri Yale, Head, Patient Affairs & Engagement, Boehringer Ingelheim
Trellis Usher, Founder & CEO, Nova Health Labs
